​

Carisma Therapeutics Ownership | Who Owns Carisma Therapeutics?

OverviewForecastRevenueFinancialsChart

Carisma Therapeutics Ownership Summary

Carisma Therapeutics is owned by 9.53% institutional investors, 27.76% insiders, and 62.71% retail investors. Merck is the largest institutional shareholder, holding 3.53% of CARM shares.

CARM Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockCarisma Therapeutics9.53%27.76%62.71%
SectorHealthcare Stocks 492.67%11.09%-403.76%
IndustryBiotech Stocks 295.31%11.22%-206.53%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Merck1.47M3.53%$403.67K
Vanguard group350.32K0.84%$95.99K
Blackrock funding, inc. /de336.79K0.81%$92.28K
Geode capital management250.50K0.60%$68.65K
Gts securities50.12K0.12%$19.65K
Empowered funds30.99K0.07%$12.13K
Blodgett wealth advisors24.00K0.06%$6.58K
Two sigma securities17.95K0.04%$7.03K
Dynamic financial group15.35K0.04%$4.21K
Citigroup11.27K0.03%$3.09K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Merck1.47M0.18%$403.67K
Blodgett wealth advisors24.00K0.00%$6.58K
Dynamic financial group15.35K0.00%$4.21K
Gts securities50.12K0.00%$19.65K
Two sigma securities17.95K0.00%$7.03K
Empowered funds30.99K0.00%$12.13K
Carolina wealth advisors150.00-$41.00
Baader bank aktiengesellschaft---
Tower research capital llc (trc)---
Barclays---

Top Buyers

HolderShares% AssetsChange
Gts securities50.12K0.00%50.12K
Citigroup11.27K-11.27K
Two sigma securities17.95K0.00%6.34K
Raymond james financial75.00-75.00
Geode capital management250.50K--

Top Sellers

HolderShares% AssetsChange
Aju ib investment---718.33K
Barclays---549.30K
Millennium management---120.16K
Hrt financial lp---36.90K
Stratos wealth partners---22.20K

New Positions

HolderShares% AssetsChangeValue
Gts securities50.12K0.00%50.12K$19.65K
Citigroup11.27K-11.27K$3.09K
Raymond james financial75.00-75.00$29.00

Sold Out

HolderChange
Peoples bank/ks-250.00
Bank & trust-525.00
Federated hermes-5.63K
Tower research capital llc (trc)-7.83K
Stonex group-10.73K

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 202534-2.86%3,982,439-2.93%99.78%10-28.57%6-
Mar 31, 202536-5,576,15716.58%1310.13%14-6.67%6-14.29%
Dec 31, 2024382.70%4,888,967-6.07%117.50%1645.45%7-41.67%
Sep 30, 202437-24.49%5,205,020-14.78%125.80%11-60.71%12-7.69%
Jun 30, 202449-2.00%6,107,691-28.20%143.40%2855.56%13-31.58%

Recent Insider Transactions

DateNameRoleActivityValue
Oct 07, 2025Klichinsky Michael Chief Scientific OfficerSell$14.48K
Oct 01, 2025Klichinsky Michael Chief Scientific OfficerSell$42.41K
Oct 02, 2025Klichinsky Michael Chief Scientific OfficerSell$50.86K
Oct 03, 2025Klichinsky Michael Chief Scientific OfficerSell$31.08K

Insider Transactions Trends

DateBuySell
2025 Q4-4
2025 Q1--
2024 Q4--
2024 Q3--
2024 Q2--

CARM Ownership FAQ

Who Owns Carisma Therapeutics?

Carisma Therapeutics shareholders are primarily institutional investors at 9.53%, followed by 27.76% insiders and 62.71% retail investors. The average institutional ownership in Carisma Therapeutics's industry, Biotech Stocks , is 295.31%, which Carisma Therapeutics falls below.

Who owns the most shares of Carisma Therapeutics?

Carisma Therapeutics’s largest shareholders are Merck (1.47M shares, 3.53%), Vanguard group (350.32K shares, 0.84%), and Blackrock funding, inc. /de (336.79K shares, 0.81%). Together, they hold 5.17% of Carisma Therapeutics’s total shares outstanding.

Does Blackrock own Carisma Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Carisma Therapeutics.

Who is Carisma Therapeutics’s biggest shareholder by percentage of total assets invested?

Merck is Carisma Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.18% of its assets in 1.47M Carisma Therapeutics shares, valued at 403.67K$.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools